A phase 3 trial in adults with prurigo nodularis (PN) treated with dupilumab measures reduction in itch and lesion count.

Researchers assessed the efficacy of customized skin care emollients for the treatment of babies and children with atopic dermatitis.

The relationship of attaining PASI 100 and achieving optimal HRQOL during the open-label treatment phase of the 5-year VOYAGE 1 and 2 trials is investigated.

Long-term maintenance of complete skin clearance in response to guselkumab treatment in patients with psoriasis in various areas is assessed.

Investigators assess the long-term efficacy of guselkumab for the treatment of scalp and nail psoriasis.